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Summary A number of polyunsaturated fatty acids have been shown to inhibit the growth of malignant cells
in vitro. To investigate whether fatty acids modify the growth of human pancreatic cancer, lauric, stearic,
palmitic, oleic, linoleic, alpha-linolenic, gamma-linolenic, arachidonic, docosahexaenoic and eicosapentaenoic
(EPA) acids were each incubated with the cells lines MIA PaCa-2, PANC-1 and CFPAC at concentrations
ranging from 1.25 JAM to 5011M and the effect of each fatty acid on cell growth was examined. All the
polyunsaturated fatty acids tested had an inhibitory effect, with EPA being the most potent (ID50 2.5-5gM).
Monounsaturated or saturated fatty acids were not inhibitory. The action of EPA could be reversed with the
anti-oxidant vitamin E acetate or with oleic acid. The cyclo-oxygenase inhibitors indomethacin and piroxicam
had no effect on the action of EPA. The action of EPA appeared to be associated with the generation of lipid
peroxides, although the level of lipid peroxidation did not always appear to correlate directly with the extent
of cell death. The ability of certain fatty acids to inhibit significantly the growth of three human pancreatic
cancer cell lines in vitro at concentrations which could be achieved in vivo suggests that administration of such
fatty acids may be of therapeutic benefit in patients with pancreatic cancer.
Pancreatic cancer is now the fifth commonest cause of cancer
death in the Western world (Williamson, 1988). Despite
recent improvements in diagnosis and staging, the prognosis
remains very poor, with a median survival of approximately
3-6 months (Cancer of the Pancreas Task Force Group,
1981; Williamson, 1988). Surgical resection of early disease
offers the only chance of long-term survival but is rarely
feasible since most patients present with advanced disease
(Carter, 1989). Pancreatic cancer is also associated with sub-
stantial morbidity. For example, patients have a very high
incidence of cachexia (DeWys, 1986), and indeed progressive
weight loss is often the major symptom experienced. Clearly
the best way to reverse such cachexia is to provide effective
treatment of the cancer (Calman, 1982). However, at present
there is no effective systemic antineoplastic therapy for
advanced pancreatic cancer (Carter, 1989), and the toxicity of
conventional chemotherapy may contribute further to the
deteriorating nutritional status of the patient. Hence there is
an urgent need for new, selective, non-toxic treatments for
advanced pancreatic malignancy.
A number of studies have suggested that certain polyun-
saturated fatty acids (PUFAs) can inhibit the growth of a
variety of human cancer cell lines in vitro (Wica et al., 1979;
Dippenaar et al., 1982; Fugiwara et al., 1983; Begin et al.,
1985, 1986). Moreover, the effects of PUFAs have been
shown to be selective for cancer cells without affecting nor-
mal cells in vitro (Begin et al., 1986). Although enhanced
lipid peroxidation has been proposed as one of the main
mechanisms by which PUFAs inhibit tumour cell growth in
vitro (Begin et al., 1988), it is not clear whether this is the
case with all cell lines, nor is it known which peroxidation
products are important in tumour cell killing.
It has been suggested that the presence of albumin in the
culture medium may decrease the anti-tumour effects of free
fatty acids in vitro (Hayashi et al., 1990), but this has not
been tested using human cancer cell lines. In addition, a
variety of antioxidants such as vitamin E, oleic acid and
sodium selenite (Begin et al., 1988) have been shown to
decrease the anti-cancer effects of PUFAs in vitro. Since these
antioxidants are often present in vivo, such findings bring
into question whether PUFAs might be effective anticancer
agents in patients. Recent studies have, however, demon-
strated the growth-inhibitory effects of diets supplemented
with the PUFAs eicosapentaenoic acid (EPA) and gamma-
linolenic acid in a variety of tumour-bearing mouse models
(Karmali et al., 1984, 1987; Pritchard et al., 1989; Beck et al.,
1991).
In order to test the potential of PUFAs for the treatment
of patients with pancreatic cancer, the effects of a variety of
fatty acids on the growth of three human pancreatic cancer
cell lines was examined. Since free fatty acids are normally
bound to albumin in vivo, fatty acids complexed to albumin
were used. Lipid peroxidation and the metabolism of fatty
acids by the cyclo-oxygenase pathway represent potential
mechanisms for the inhibition of tumour cell growth by
PUFAs. With a view to optimising the anti-cancer effects of
PUFAs in vivo, the in vitro effects of manipulating these
pathways were also studied.
Materials and methods
Reagents
Palmitic acid, stearic acid, lauric acid, linoleic acid, alpha-
linolenic acid, arachidonic acid, gamma-linolenic acid,
docosahexaenoic acid, eicosapentaenoic acid (EPA), fatty
acid-free bovine serum albumin (BSA), indomethacin,
vitamin E acetate, piroxicam and ferrous chloride were
obtained from Sigma (Sigma, Poole, Dorset, UK). Malon-
dialdehyde (MDA), thiobarbituric acid and trichloroacetic
acid were obtained from BDH (Glasgow, UK). [3H]thymidine
was obtained from Amersham (Buckinghamshire, UK). Fatty
acids were complexed to BSA according to the method of
Mahoney et al. (1977) and 1 mM stock solutions were stored
at -20°C. Subsequent analysis of the stock solutions by
gas-liquid chromatography (Hudson et al., 1993) indicated
that there was no significant degradation of the fatty acids
during the complexing process. Eicosanoid inhibitors were
dissolved in 100% ethanol and ferrous chloride was dissolved
in 150mM sodium chloride and stock solutions were stored
at -20°C.
Cell lines
The human pancreatic cancer cell lines MIA PaCa-2, PANC-
1 and CFPAC were obtained from the European Tissue
Culture Collection, Porton Down, UK. Cell lines were
routinely grown in Dulbecco's modified Eagle medium sup-
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plemented with 5% fetal bovine serum (ICN Biomedicals,
Irvine, Ayrshire, UK), 1 mM glutamine and penicillin/
streptomycin (Sigma) in a 95% air/5% carbon dioxide
humidified incubator. The same batch of fetal bovine serum
was used for all experiments to minimise effects due to
inter-batch variability.
Growth experiments
Cells were routinely seeded in 96 well flat-bottomed micro-
plates (Costar Corporation, Cambridge, UK) at a density of
5 x I03 cells per well in 100 il of medium and incubated for
24 h before supplementation of the medium with fatty acid
complexed to BSA. Fatty acid and/or eicosanoid inhibitors
were added to give a final volume of 120pl. When agents
dissolved in ethanol were added the final concentration of
ethanol was 0.5% or less and ethanol alone was added to the
control wells. In experiments designed to examine the effect
of fatty acid alone, cells were routinely incubated for a
further 6 days with the relevant fatty acid. At the end of the
incubation period cell numbers were assessed by a
modification of the method of Matsubara et al. (1991).
Briefly, the medium was removed and any adherent cells were
fixed to the plate with 5% formaldehyde in phosphate-
buffered saline (PBS). The cells were then stained with a
0.5% aqueous solution of crystal violet followed by elution
of the dye with 33% aqueous acetic acid. Absorbance at
570 nm was determined with a Dynatech 5000 microplate
reader (Dynatech Laboratories, Billingshurst, West Sussex,
UK) and the number of cells was determined from a stan-
dard curve of absorbance against cell numbers calculated
from a mean of six experiments for each cell line (R2 = 0.99).
When the effect of fatty acids on cell viability was assessed,
this was measured by trypan blue exclusion and the results
were expressed as the percentage of viable cells at the end of
the incubation period. When thymidine uptake was
measured, the cells were incubated with 1 iLCi of [3H]thymi-
dine for 4 h at the end of the incubation period. The cells
were then harvested onto filter paper using a Dynatech
AUTOMASH 2000 cell harvester, placed in 5 ml of liquid
scintillant and [3H]thymidine uptake was measured using a
Packard Tri-carb 300C counter (Packard Instrument,
Downers Grove, IL, USA).
Lipidperoxidation experiments
Polyunsaturated lipids are highly susceptible to lipid peroxi-
dation, giving rise to various alkenal and aldehyde
metabolites (Halliwell & Gutteridge, 1985). A number of
these metabolites, including malondialdehyde (MDA), react
with thiobarbituric acid to produce a pink-coloured material
that can readily be monitored by spectrophotometry to give
an overall indication of the level of lipid peroxidation (Hal-
liwell & Gutteridge, 1985). Cells were cultured in 25 cm2
flasks at an initial concentration of 5 x 105 or 1 x 106 cells in
10 ml of standard medium. EPA supplementation and other
additions were carried out after 24 h incubation. Lipid
peroxidation was measured according to the method of
Gavino et al. (1981). Briefly, at the end of the incubation
period, the supernatant was removed and centrifuged to
recover any non-adherent cells. Both non-adherent cells and
cells adherent to the flask were washed with 0.9% sodium
chloride until all the colour of the medium was removed and
then the pooled cells were resuspended in a final volume of
2 ml of PBS. Two millilitres of 20% trichloroacetic acid and
2 ml of 0.67% thiobarbituric acid was then added, this mix-
ture was incubated at 90°C for 20 min and the supernatant
was then centrifuged to remove any debris. The absorbance
of the supernatant at 532 nm was then measured against that
of a reagent blank treated similarly but containing no cells.
Absorbance was converted to picomoles (pmol) of MDA
equivalents using a standard curve generated with MDA,
62.5- 6,250 pmol (R2 = 1.00 in three experiments).
In addition, the total protein content of the flasks was
assayed to give a measure of the biomass of cells in the
flasks. Following the measurement of lipid peroxides, the
cells were removed from the flasks, resuspended in 0.9%
sodium chloride and washed twice with 0.9% sodium
chloride. A 450 tl volume of 2 M sodium hydroxide was then
added to the cell pellet, which was left for 18 h at room
temperature followed by 1 h of heating at 60°C to dissolve
the pellet. The resulting solution was partially neutralised
with 350 tlI of 2 M hydrochloric acid and aliquots were then
assayed for protein content using the Coomassie brilliant
blue method of Bradford (1976) with BSA as a standard.
Biomass was expressed as micrograms of protein per flask. A
duplicate set of flasks were processed to allow the assessment
of cell viability by the method of trypan blue exclusion.
Results were expressed as the percentage of viable cells at the
end of the incubation period.
Statistics
Statistical analysis was carried out using a two-tailed Student's
t-test, and differences were regarded as significant when the
chance of their arising by sampling error was less than 1 in
20 (P<0.05).
Results
Effects offatty acids on cell numbers
All of the PUFAs tested (alpha-linolenic acid, linoleic acid,
arachidonic acid, docosahexaenoic acid, gamma-linolenic
acid and EPA) significantly reduced the growth rate of the
three pancreatic cancer cell lines in a dose-dependent manner
(Figure 1). Of the PUFAs tested, EPA was the most effective
inhibitor, with a greater than 90% reduction in cell numbers
at the highest concentrations tested.
In contrast, none of the saturated fatty acids (palmitic
acid, stearic acid and lauric acid) or the monounsaturated
acid (oleic acid) had any inhibitory effect on growth (Figure
2). Indeed, palmitic acid, lauric acid and oleic acid all
significantly enhanced growth at some concentrations (Figure
2).
Effects offatty acids on cell viability
The effect on the viability of MIA PaCa-2 cells after 6 days'
incubation of EPA, gamma-linolenic acid, oleic acid and
palmitic acid at a variety ofconcentrations is shown in Table
I. Both PUFAs resulted in a significant loss of viability in a
dose-dependent manner, with EPA being the more effective.
Oleic acid and palmitic acid had no significant effect.
Effects ofEPA on cellproliferation
In order to discriminate between an effect of EPA on the rate
of cell growth as opposed to cell death, thymidine uptake
was used as an index of DNA synthesis, while cell number
was used to estimate any net change in biomass. Figure 3
shows the effect of increasing concentrations of EPA on the
growth of MIA PaCa-2 over a 7 day period when both
absolute cell number and tritiated thymidine uptake were
measured. A significant inhibitory effect of EPA on cell
numbers was observed after 3 days' incubation, and the
magnitude of this inhibition increased with time. Similarly,
the inhibition of thymidine uptake by EPA became apparent
after 2-3 days and the magnitude of the inhibition increased
with time. Expression of thymidine uptake per cell also
revealed that the inhibitory effect of EPA only became ap-
parent after 3 days' incubation and that the magnitude of the
effect increased with increasing concentrations of EPA.
Effect ofmedium replenishment
In order to establish whether the effect of EPA may be
mediated indirectly via a metabolic or degradation product
of EPA accumulating in the culture medium, MIA PaCa-2828 J.S. FALCONER et al.
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Figure 1 Effect ofincreasing concentrations of the fatty acids (a) alpha-linolenic acid (ALA), (b) linoleic acid (LA), (c) arachidonic
acid (AA), (d) gamma-linolenic acid (GLA), (e) docosahexaenoic acid (DHA) and (f) eicosapentaenoic acid (EPA) on the growth of
the three human pancreatic cancer cell lines MIA PaCa-2 (0), PANC-1 (0) and CFPAC (e) over a 7 day period. Cell numbers
were measured using the crystal violet technique and are expressed as a percentage of control values (without fatty acid). Each
point represents the mean of at least three separate experiments. The largest coefficient of variation for each set of experiments was
(a) 20.0%, (b) 18.4%, (c) 7.9%, (d) 8.4%, (e) 11.6% and (f) 6.4%.
cells were incubated with and without EPA supplementation
and were either left to grow in the medium over a 5 day
period or had the medium and EPA supplementation
changed daily. The results are shown in Table II. There was
no significant difference between the inhibition achieved with
EPA at various concentrations whether or not the EPA-
supplemented medium was replaced on a daily basis.
Effects ofvariousfatty acids in combination
Figure 4 shows the effect of EPA alone and in combination
with the fatty acids oleic acid, linoleic acid, arachidonic acid
and palmitic acid at increasing concentrations. Oleic acid at
2.5 LM abrogated the inhibitory effect of EPA completely
and, of the fatty acids tested, this effect was unique to oleic
acid.
Effects ofantioxidants and inhibitors
The effects of a variety of antioxidants and inhibitors at
increasing concentrations in combination with a fixed
concentration of 30 ItM EPA on MIA PaCa-2 cells are shown
in Figure 5. The agents examined were oleic acid, vitamin E
acetate (antioxidant), piroxicam (cyclo-oxygenase inhibitor;
Carty et al., 1980) and indomethacin [which is primarily a
cyclo-oxygenase inhibitor but at high concentrations is able
to inhibit both phospholipase A2 (Kaplan et al., 1978) and
lipoxygenase (Vanderhoek et al., 1984)]. Only oleic acid and
the antioxidant vitamin E acetate were able to abrogate the
effect of EPA, with both piroxicam and indomethacin having
no effect.
The role oflipidperoxidation
The relationship between the generation of lipid peroxides
(measured as thiobarbituric acid-reactive material), cell
growth (measured as the protein content of the culture flasks)
and cell viability in flasks seeded with 1 x 106 MIA PaCa-2
cells supplemented with increasing concentrations of EPA is
shown in Table III. As the concentration of EPA increased,
so the level of lipid peroxides increased, and this was
associated with loss of cell viability.
The effects of EPA, vitamin E acetate and ferrous chloride
on lipid peroxide production, cell growth and cell viability
6
0
u
120
100
80
60
40
20
0
6
C
0
u
120
100
80
60
40
20
0
120
100
80
60
40
--! 6
0
u
20
0 vEFFECTS OF FATTY ACIDS ON PANCREATIC CANCER CELLS 829
SA
LEE - p
a
6
C
0
150 7
100 q
50 -
a
0 10 20 30 40 50
F.M fatty acid
c
PA
6
0
u
150-
100
50-
0
0 10 20 30 40 50
F.M fatty acid
b
LauA
0 10 20 30 40 50
FM fatty acid
d
OA
I 0 20I I
0 10 20 30
I '
40 50
F.M fatty acid
Figure 2 Effect of increasing concentrations of the fatty acids (a) stearic acid (SA), (b) lauric acid (Lau A), (c) palmitic acid (PA)
and (d) oleic acid (OA) on the growth of the three human pancreatic cancer cell lines MIA PaCa-2 (0), PANC-1 (0) and
CFPAC (-) over a 7 day period. Cell numbers were measured using the crystal violet technique and are expressed as a percentage
of control values (without fatty acid). Each point represents the mean of at least three separate experiments. The largest coefficient
of variation for each set of experiments was (a) 13.4%, (b) 21.3%, (c) 19.6% and (d) 12.4%.
Table I Effect on viability of MIA PaCa-2 cells after 6 days' incubation with
different concentrations of EPA, gamma-linolenic acid (GLA), oleic acid (OA) and
palmitic acid (PA)a'b
Fatty acid conc. Viable cells (%)
(4M) EPA GLA OA PA
0 94.7 (3.4) 96.2 (3.7) 98.7 (2.9) 93.7 (3.5)
2.5 74.7 (12.4)* 89.1 (7.9) 97.3 (2.2) 92.5 (6.9)
5 56.0 (4.1)** 68.4 (6.7)* 96.8 (2.6) 97.5 (4.8)
10 33.3 (4.0)** 41.3 (4.6)** 98.0 (5.8) 93.8 (2.5)
20 8.5 (2.5)** 27.0 (3.7)** 95.0 (2.9) 94.2 (2.5)
40 5.7 (3.4)** 11.3 (5.7)** 98.8 (1.7) 98.0 (2.0)
aResults are mean (s.d.). bCell viability was assessed using trypan blue exclusion.
*P<0.05, **P<0.01 vs control (no fatty acid supplementation).
using flasks seeded with 5 x 105 MIA PaCa-2 cells is shown
in Table IV. At low concentrations of EPA (5 JM), cell
growth and viability were not inhibited significantly. There
was, however, a small but significant increase in the level of
thiobarbituric acid-reactive material produced compared with
that found in cells cultured in the absence of EPA. At higher
concentrations of EPA (50 JM), cell protein mass was reduced
significantly, as was cell viability. This was associated with a
significant increase in the levels of thiobarbituric acid-reactive
material when compared with cells not supplemented with
EPA. The pro-oxidant ferrous chloride significantly enhanced
both the levels of lipid peroxide and the inhibitory effect of
EPA (5 JAM) on cell growth and cell viability. Conversely, in
the presence of the antioxidant vitamin E acetate, the effect
of EPA (50 JAM) on cell growth and the level of lipid peroxi-
dation products generated was completely reversed.
Table V shows the results of a similar set of experiments
using flasks seeded with 1 x 106 MIA PaCa-2 cells where
EPA was added in combination with oleic acid. Oleic acid
had been shown to abrogate the growth-inhibitory effects of
EPA in the 96 well microplate experimental system (Figures 4
and 5). In the experiments shown in Table V, the greater cell
density resulted in the levels of peroxide generated being
greater than in the previous set of experiments (see Table
IV). Again 50 JAM EPA caused a significant reduction in cell
growth and cell viability, and this was associated with in-
creased generation of lipid peroxides. Oleic acid alone at
concentrations of 5 JAM and 50 JM had no effect on cell
growth or peroxide formation. Supplementation of medium
with 50 JAM and 5 JM oleic acid did not alter the effects
observed with 50 JAM EPA alone. In contrast, the combina-
tion of 50 JAM oleic acid with 50 JAM EPA resulted in a
complete abrogation of the growth-inhibitory effects of EPA,
but the total levels of lipid peroxides generated were un-
altered and were not significantly different from those seen
with EPA alone, although the amount of lipid peroxides
generated on day 1 was lower in the flasks containing 50 JM
oleic acid and 50 JAM EPA.
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Discussion
These experiments demonstrate that a range of PUFAs can
inhibit significantly the growth of three human pancreatic
cancer cell lines in vitro and that EPA is the most effective
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inhibitor (Figure 1). In contrast, saturated fatty acids and the
monounsaturated oleic acid have no effect (Figure 2). This
growth-inhibitory effect is associated with a significant loss of
cell viability (Table I). The inhibitory effect of EPA appears
to be both dose and time dependent, with a significant reduc-
tion in cell numbers apparent after 2 days (Figure 3). EPA
reduces the uptake of tritiated thymidine by the pancreatic
cancer cells over the same time course (Figure 3). This sug-
gests that EPA may act mainly by inhibiting cell proliferation
rather than by accelerating cell death, as the thymidine
uptake per cell decreased with increasing concentrations of
EPA.
The similarity between the growth inhibition achieved
when EPA-supplemented medium was changed every day,
and that seen when the same medium was present through-
out the incubation period (Table II) suggests that the
inhibitory effect of EPA is not mediated by means of a toxic
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Figure 5 Effect of increasing concentrations of piroxicam (A),
indomethacin (0), vitamin E acetate (0) (conc. x 0.2) and oleic
acid (-) on the growth-inhibitory effects observed with 30 ISM
EPA on MIA PaCa-2 cells over a 7 day period with zero on the
x-axis representing the effect of EPA alone. Cell numbers were
measured using the crystal violet technique and are expressed as a
percentage of control values (without EPA). Each point
represents the mean of at least three separate experiments. The
largest coefficient of variation for these experiment was
21.2%.
Figure 3 Changes in (a) cell numbers measured using the crystal
violet technique, (b) tritiated thymidine incorporation and (c)
tritiated thymidine incorporation per cell of MIA PaCa-2 cells
when incubated without (0) or with EPA at 1.25 IgM (0), 2.5 tLM
(0), 5 4M (A) and IO JM (M) over a 7 day period. Cells were
seeded on day 0 and EPA was added on day 1. The experiment
was repeated on three separate occasions and each point
represents the mean of quadruplicate wells from one such experi-
ment. The largest coefficient of variation for this experiment was
8.7%.
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Figure 4 Effect of S gSM EPA alone (no second fatty acid added)
and increasing concentrations of a second fatty acid, linoleic acid
(0), oleic acid (U), arachidonic acid (0) or palmitic acid (0),
on the growth of MIA PaCa-2 cells over a 7 day period. Cell
numbers were measured using the crystal violet technique and are
expressed as a percentage of control values (without EPA or
second fatty acid). Each point represents the mean of at least
three separate experiments. The largest coefficient of variation for
these experiment was 18.7%.
Table II Effect of EPA on the growth of MIA PaCa-2 cells over a 5
day period with either the medium (and EPA supplementation)
changed daily or with the same medium present throughout the
incubation periodab
EPA conc. (ISM)
2.5 5 10
Medium changed every 24h 77.7 (3.5) 31.7 (4.5) 11.0 (7.0)
Medium not changed 74.7 (3.5) 34.0 (5.0) 11.7 (6.5)
aResults are mean (s.d.) cell number expressed as a percentage of
control (without EPA) values. bCell growth was assessed using the
crystal violet technique.
Table III Thiobarbituric acid-reactive material generated, protein
content and percentage viable cells in 25 cm2 flasks with 1 x 106 MIA
PaCa-2 cells supplemented with increasing concentrations of
EPAa
EPA conc. Lipid peroxide" Proteinc Viable cells
(AM) (pmol _ MDA per flask) (jig per flask) (%)d
0 340 (26) 818 (14) 99.9
6.25 810 (150)* 873 (39) 99.8
12.5 1073 (55)** 646 (22)* 91.6
25 1637 (119)** 237 (17)** 0.7**
50 2901 (332)** 171 (13.5)** 2.2**
aResults are mean (s.e.m.). bMean daily lipid peroxide production
for days 1-3 expressed as pmol of MDA equivalent per flask. cTotal
protein content of flask at day 3 expressed as pg of protein per flask.
dPercentage of viable cells was assessed by trypan blue exclusion at
day 3.
*P<0.05, **P<0.01 vs control (no EPA).
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Table IV Thiobarbituric acid-reactive material generated, protein content and
percentage viable cells in 25 cm2 flasks with 5 x 105 MIA PaCa-2 cells supplemented
with EPA and ferrous chloride (40gigml-') and vitamin E acetate (5 gM)a
Additive
0
EPA (5gM)
EPA (5011M)
EPA (5 JiM) + FeC12
EPA (50pM) + vit. E
Lipid peroxideb
(pmol_ MDA per flask)
226 (43)
388 (42)*
925 (95)**
865 (110)**
256 (87)
Proteinc
(gLg per flask)
666 (45)
424 (78)
76 (9)**
270 (48)**
659 (24)
Viable cells
(%)d
91.8 (4.0)
94.9 (2A)
3.9 (2.5)**
53.3 (10.5)**
91.5 (1.9)
aResults are mean (s.e.m.). of three separate experiments. bMean daily lipid
peroxide production for days 1-3 expressed as pmol of MDA equivalent per flask.
cTotal protein content of flask at day 7 expressed as Aig of protein per flask.
dPercentage of viable cells was assessed by trypan blue exclusion at day 7.
*P<0.05, **P<0.01 vs no additive.
Table V Thiobarbituric acid-reactive material generated, protein content and percentage
viable cells in 25 cm2 flasks with 1 x 106 MIA PaCa-2 cells supplemented with increasing
concentrations 50 giM EPA and/or 511M and 50 JAM oleic acid (OA)'
Lipid peroxideb Proteinc Viable cells
Additive (pmol _ MDA per flask) (gig per flask) (%)d
0 321 (24) 1169 (145) 99.3 (0.3)
OA (5 JM) 333 (63) 1209 (99) 99.4 (1.2)
OA (501M) 401 (52) 1168 (51) 99.3 (0.7)
EPA (50 gM) 2759 (138)** 319 (59)** 5.4 (1.5)**
EPA (50 IM) + OA (51M) 2872 (152)** 382 (71)** 7.6 (4.7)**
EPA (5011M)+OA (50I1M) 2572 (210)** 1086 (43) 98.6 (0.7)
aResults are mean (s.e.m.). of four separate experiments. bMean daily lipid peroxide
production for days 1-3 expressed as pmol of MDA equivalent per flask. cTotal protein
content offlask at day 3 expressed as gig ofprotein per flask. dPercentage of viable cells was
assessed by trypan blue exclusion at day 3.
**P <0.01 vs control (no EPA).
metabolite of EPA accumulating in the cell culture medium.
However, this does not exclude the generation of a toxic
metabolite within the cell itself, nor does it exclude the
generation of a toxic product in the medium within the 24 h
prior to the replacement of the medium.
Both the antioxidant vitamin E acetate and oleic acid
(which also has antioxidant properties; Diplock et al., 1988)
were able to reverse the growth inhibition achieved with
EPA. The cyclo-oxygenase inhibitors piroxicam and indo-
methacin had no effect (Figure 5). As proposed previously by
Begin et al. (1988) and Canuto et al. (1991), this suggests that
an oxidative process is involved in the effects of PUFAs on
malignant cell lines rather than a cyclo-oxygenase-generated
product. The inhibition of growth of the pancreatic cancer
cell lines observed in the present study occurred at lower
concentrations of PUFA than others have described with
different, non-pancreatic, malignant cell lines (Dippenaar et
al., 1982; Fugiwara et al., 1983; Begin et al., 1985, 1986,
1988; Canuto et al., 1991), indicating that pancreatic cancer
cells may be particularly sensitive to the effects of PUFAs, at
least in vitro.
Non-programmed cell death (from any cause) results in the
eventual degradation of cell membranes and the generation
of lipid peroxides. In the present study the levels of lipid
peroxide generated on days 1-3 following the addition of
EPA (i.e. before and during cell death) were assessed to try
and ensure that non-specific peroxidation of dead cells did
not bias the results. There was a marked increase in the level
of lipid peroxides generated by the cells supplemented with
increasing concentrations of EPA, and this was associated
with a significant inhibition in cell growth and loss of cell
viability (Table III).
The concentration at which PUFAs can cause a loss of cell
viability and inhibit cell growth is known to vary depending
on the cell density (Begin et al., 1985, 1986). However, the
concentration at which EPA had an inhibitory effect on cell
growth was higher in the experiments performed using cells
grown in 25 cm2 flasks than when the cells were grown in 96
well microplates, despite the seeding concentrations being
approximately the same (5 x IO0 to 1 x IO0 cells ml-'). The
most likely reason for this finding is differences in the cell
densities in the monolayer microenvironments of the two
culture systems, with the cells being more closely apposed in
the 25 cm2 flasks.
The association between the levels of lipid peroxides
generated and the inhibition in cell growth shown in Table
III might suggest a causal relationship. However, although
the level of lipid peroxides generated by cells supplemented
with 5 JAM EPA could be markedly augmented by the addi-
tion of the pro-oxidant ferrous chloride to the medium
(Table IV), the associated reduction in cell biomass and
viability was less marked. In fact, the levels of lipid peroxide
generated with 5 JLM EPA and ferrous chloride were virtually
identical to the levels generated by 50 JM EPA, yet the loss
of cell viability and the reduction in cell numbers (biomass)
were significantly greater with 50 JM EPA (Table IV). In
addition, the combination of 50JM oleic acid and 50JM
EPA resulted in a complete abrogation of the inhibitory
effects of EPA (Table V) yet had no significant effect on the
overall levels of lipid peroxides produced. The fact that
similar levels of lipid peroxidation were present in circum-
stances which could result in such different extents of growth
inhibition and loss of cell viability suggests that lipid peroxi-
dation may not be the only factor involved in PUFA-induced
cell death.
Begin et al. (1988), using a similar method of measuring
lipid peroxidation in a breast cancer cell line, were able to
show a correlation between the extent of cell death induced
by various fatty acids and the levels of lipid peroxide
generated. They also demonstrated that vitamin E inhibited
both lipid peroxide formation and PUFA-induced loss of cell
viability and that the antiproliferative effects of the PUFA
gamma-linoleic acid could be enhanced using pro-oxidants.
These findings were interpreted as indicating that lipid832 J.S. FALCONER et al.
peroxidation was the cause of cell death when in fact they
may only indicate that it occurs in association with cell
death. The thiobarbituric acid assay system, however, is a
relatively imprecise method of measuring lipid peroxidation
products and only gives a measure of total peroxidation
products. It is certainly possible that a single specific lipid
peroxidation metabolite is responsible for the effect of
PUFAs rather than 'lipid peroxides' as a whole, and further
studies will need to be carried out to determine whether or
not this is the case.
The plasma free fatty acid concentration in the fed state is
approximately 300 JLM and can reach as high as 2,000tLM
following prolonged exercise, fasting or stress (Newsholme &
Leech, 1983). Previous studies of oral EPA supplementation
in control subjects have demonstrated that it is possible to
increase the EPA content of plasma phospholipids from 1%
to 5-7% (Bronsgeest-Schoute et al., 1981; Thorngren et al.,
1986). Such an increase in the levels of free fatty acid would
represent a plasma EPA concentration of 15-21 jLM in the
fed state and possibly concentrations as high as 100-140YM
in the exercised, fasted or stressed state. The concentration of
fatty acid in the immediate environment of a tumour is likely
to be only a fraction of the concentration present in the
plasma but, nevertheless, it could still be possible to achieve
EPA concentrations in the tumour microenvironment which
have been shown to have an anti-cancer effect in vitro.
In summary, this study has shown that relatively low
concentrations of certain PUFAs (in particular EPA), which
may be achievable in vivo, are able to inhibit the growth in
vitro of three human pancreatic cancer cell lines. The effect
may well be due to an oxidative process other than lipid
peroxidation or one specific metabolite formed by lipid
peroxidation. The in vivo effects of PUFAs are likely to be
far more complex and influenced by numerous other factors.
Nevertheless, the present data suggest that polyunsaturated
fatty acids may be of therapeutic benefit in the treatment of
patients with pancreatic cancer.
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